Press Release
For More Information, Contact Tammy McCoy (404) 633-3777
Embargoed for Release at 5:30 PM ET, Friday Oct. 24, 2003
Arthritis News
BENEFITS OF OSTEOPOROSIS TREATMENT ON FRACTURE RISK
MAY BE GREAT, EVEN WHEN IMPROVEMENT IN BONE DENSITY IS SMALL
ORLANDO, FLORIDA—A recent study revealed
that reduction in fracture risk from risedronate,
a bisphosphonate medication commonly used to
treat patients who have osteoporosis, is seen
even in
patients who have only small improvements in
bone mass as measured by bone density, according
to
research presented this week at the American
College of Rheumatology Annual Scientific Meeting
in Orlando,
Florida.
Researchers reanalyzed data from the HIP and
VERT studies of risedronate, which included nearly
9,000 patients from two randomized, double-blind
clinical trials. Patients were selected to receive
risedronate or placebo based on low bone mineral
density (an indicator of bone strength) and/or
pre-existing vertebral fracture. All patients
also received daily supplements of calcium and
vitamin
D if baseline levels were low. Researchers examined
the relationship between new vertebral fractures
and changes in lumbar spine bone mineral density
in both the placebo and risedronate groups. The
results confirm that increases in bone mineral
density results in a reduction in patients’ risk
for fracture as compared to those whose bone
mineral density decreases. Patients taking risedronate
had a decreased risk of fracture compared to
those
taking placebo. Further, the results show that
there was a significant reduction in fracture
risk in all patients who had improvements in
bone density,
and that the reduction in fracture risk was independent
of the magnitude of the improvement. Comparisons
of bone mineral density increases among different
therapies may not translate into meaningful differences
in reducing fracture risk.
Fracture is a leading
cause of disability in patients with osteoporosis,
which affects 10
million people in the U.S., the majority of whom
are women.
“Bone density measurements have helped us identify
those who are at high risk for fractures,” said
Jonathan Adachi, MD, Professor and Director of
the Arthritis Centre at St. Joseph’s Hospital-McMaster
University in Hamilton, Ontario, Canada, an investigator
on the study. “In following patients on therapy,
our study suggests that even moderate increases
in bone density offer treatment benefit that
is not significantly different from larger increases.
This suggests that there may be a threshold above
which further increases in bone density have
little
effect on fracture benefit. This also reinforces
the need for further research to determine how
osteoporosis therapies influence other elements
of bone quality that affect the risk of fracture,
such as bone turnover and bone micro-architecture.”
The
American College of Rheumatology is the professional
organization for rheumatologists and health professionals
who share a dedication to healing, preventing
disability and curing arthritis and related rheumatic
and
musculoskeletal diseases. For more information
on the ACR’s annual meeting, see www.rheumatology.org/annual.
###